With the introduction of COVID‐19 vaccines, there has been a proliferation of quantitative benefit‐risk assessments (qBRAs). Prior work on other types of vaccines has found that published qBRAs have not… Click to show full abstract
With the introduction of COVID‐19 vaccines, there has been a proliferation of quantitative benefit‐risk assessments (qBRAs). Prior work on other types of vaccines has found that published qBRAs have not always clearly reported methods and/or results needed to assist in the application of the qBRA findings. The aim was to systematically identify, review, and critically assess published COVID‐19 vaccine qBRA. The ultimate goal is to support the future development of robust qBRA for existing, new, and updated vaccines.
Journal Title: Pharmacoepidemiology and Drug Safety
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!